| HOME >> BIOLOGY >> TECHNOLOGY |
NEW HAVEN, Conn., May 5 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (Nasdaq: VION) today announced financial results for the three-month period ended March 31, 2008.
The Company reported a net loss of $8.2 million, or $1.14 per share, for the three-month period ended March 31, 2008, compared with a net loss of $8.0 million, or $1.20 per share, for the same period in 2007. Weighted-average common shares outstanding for the three months ended March 31, 2008 and 2007 were 7.2 million and 6.6 million, respectively.
Operating expenses were reduced by $679,000 from $7.9 million in the 2007 quarter to $7.2 million in 2008. Interest expense increased by $766,000 over the prior year as the Company's Convertible Senior Notes, issued in February 2007, were outstanding for the entire quarter in 2008.
The Company reported ending the quarter with $55.2 million in cash and cash equivalents, sufficient to fund the Company's operations through the third quarter of 2009 based on the current operating plan. The Company also announced that it will pay the interest payment due August 15, 2008 on its Convertible Senior Notes in cash.
Alan Kessman, Chief Executive Officer, commented, "We continue to work on the New Drug Application (NDA) for Cloretazine(R) (VNP40101M). It remains our plan to file the NDA with the U.S. Food and Drug Administration in 2008."
On February 20, 2008, the Company implemented a one-for-ten reverse split of all outstanding shares of its common stock and a corresponding decrease in the number of shares of authorized common stock. Share and per share amounts contained herein are provided on a post-split basis.
Vion Pharmaceuticals, Inc. is committed to extending the lives and improving the quality of life of cancer patients worldwide by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute myelogenous leukemia. Clinical trials of Cloretazine(R) (VNP40101M) with temozolomide in brain tumors, and with stem cell transplantation in advanced hematologic malignancies, are also being conducted. Triapine(R), a potent inhibitor of a key step in DNA synthesis, is being evaluated in clinical trials sponsored by the National Cancer Institute. For additional information on Vion and its product development programs, visit the Company's Internet web site at http://www.vionpharm.com.
This news release contains forward-looking statements. Such statements
are subject to certain risk factors which may cause Vion's plans to differ
or results to vary from those expected, including Vion's potential
inability to obtain regulatory approval for its products, particularly
Cloretazine(R) (VNP40101M), delayed or unfavorable results of drug trials,
the possibility that favorable results of earlier preclinical studies or
clinical trials are not predictive of safety and efficacy results in later
clinical trials, the need for additional research and testing, the
potential inability to secure external sources of funding to continue
operations, the inability to access capital and funding on favorable terms,
continued operating losses and the inability to continue operations as a
result, and a variety of other risks set forth from time to time in Vion's
filings with the Securities and Exchange Commission, including but not
limited to the risks attendant to the forward-looking statements included
under Item 1A, "Risk Factors" in Vion's Form 10-K for the year ended
December 31, 2007. In particular, there can be no assurance as to the
results of any of the Vion's clinical trials, that any of these trials will
continue to full accrual, or that any of these trials will not be
discontinued, modified, delayed or ceased altogether. Except in special
circumstances in which a duty to update arises under law when prior
disclosure becomes materially misleading in light of subsequent events,
Vion does not intend to update any of these forward-looking statements to
reflect events or circumstances after the date hereof or to reflect the
occurrence of unanticipated events.
-- Financial Statements Follow --
VION PHARMACEUTICALS, INC.
(A Development Stage Company)
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
Three Months Ended
March 31,
(In thousands, except per share data) 2008 2007
Technology license fee revenue $14 $5
Operating expenses:
Clinical trials 2,854 3,399
Other research and development 2,259 2,513
Total research and development 5,113 5,912
Marketing, general and administrative 2,087 1,967
Total operating expenses 7,200 7,879
Loss from operations (7,186) (7,874)
Interest income 502 667
Interest expense (1,505) (739)
Other expense, net (6) (3)
Loss before income taxes (8,195) (7,949)
Income tax provision -- 6
Net loss ($8,195) ($7,955)
Basic and diluted loss per share(1) ($1.14) ($1.20)
Weighted-average number of shares of common stock
outstanding(1) 7,173 6,636
(1) Adjusted for all periods presented to reflect the Company's
one-for-ten reverse stock split effected February 20, 2008.
CONDENSED CONSOLIDATED BALANCE SHEET DATA
(Unaudited)
March 31, Dec. 31,
(In thousands) 2008 2007
Cash and cash equivalents $55,238 $61,067
Total assets 57,170 63,195
Convertible senior notes 54,556 54,275
Total liabilities 60,673 61,988
Shareholders' equity (3,503) 1,207
COMPANY CONTACT: Vion Pharmaceuticals, Inc.
Alan Kessman, Chief Executive Officer
Howard B. Johnson, President & CFO
(203) 498-4210
'/>"/>
| SOURCE Vion Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved |
Related biology technology :
1. eResearchTechnology Reports First Quarter 2008 Results
2. MannKind Corporation Reports First Quarter Financial Results
3. Verenium Reports Financial Results for the First Quarter 2008
4. ev3 Inc. Reports 2008 First Quarter Financial Results and Revised 2008 Guidance
5. United Therapeutics Reports First Quarter 2008 Financial Results
6. Endocare Reports 2008 First Quarter Financial Results
7. AMICAS Reports Financial Results for the First Quarter Ended March 31, 2008
8. LeMaitre Vascular Reports Q1 2008 Revenue of $11.8 Million, a 20% Increase
9. Anadys Pharmaceuticals Reports First Quarter 2008 Financial Results and Highlights
10. Neurobiological Technologies Reports Receipt of $2.0 Million Royalty Payment for Quarterly Sales of Memantine
11. Alexion Reports First Quarter 2008 Results
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |